Compass TherapeuticsCMPX
CMPX
About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Employees: 35
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
118% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 17
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
15% more funds holding
Funds holding: 79 [Q3] → 91 (+12) [Q4]
6.63% more ownership
Funds ownership: 67.03% [Q3] → 73.67% (+6.63%) [Q4]
13% less capital invested
Capital invested by funds: $170M [Q3] → $147M (-$22.7M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
220%
upside
Avg. target
$14.80
492%
upside
High target
$32
1,180%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 26% 1-year accuracy 73 / 279 met price target | 1,180%upside $32 | Buy Maintained | 27 Feb 2025 |
Guggenheim Michael Schmidt 40% 1-year accuracy 12 / 30 met price target | 380%upside $12 | Buy Initiated | 24 Feb 2025 |
Piper Sandler Biren Amin 14% 1-year accuracy 3 / 22 met price target | 380%upside $12 | Overweight Initiated | 19 Feb 2025 |
Jefferies Maury Raycroft 10% 1-year accuracy 1 / 10 met price target | 220%upside $8 | Buy Maintained | 10 Feb 2025 |
HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 75 / 411 met price target | 300%upside $10 | Buy Reiterated | 10 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.
Positive
Zacks Investment Research
1 month ago
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
MarketBeat
1 month ago
Top 3 High-Momentum Companies Analysts Are Still Bullish On
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading strategies rather than long-term investing.
Positive
Zacks Investment Research
1 month ago
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
Positive
Zacks Investment Research
3 months ago
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
3 months ago
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor.
Neutral
Seeking Alpha
3 months ago
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors.
Neutral
GlobeNewsWire
3 months ago
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024.
Positive
Zacks Investment Research
3 months ago
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
3 months ago
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charts implemented using Lightweight Charts™